GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yuhan Corp (XKRX:000100) » Definitions » Notes Receivable

Yuhan (XKRX:000100) Notes Receivable : ₩0 Mil (As of Mar. 2024)


View and export this data going back to 1962. Start your Free Trial

What is Yuhan Notes Receivable?

Yuhan's Notes Receivable for the quarter that ended in Mar. 2024 was ₩0 Mil.


Yuhan Notes Receivable Historical Data

The historical data trend for Yuhan's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yuhan Notes Receivable Chart

Yuhan Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Yuhan Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Yuhan Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Yuhan Notes Receivable Related Terms

Thank you for viewing the detailed overview of Yuhan's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Yuhan (XKRX:000100) Business Description

Traded in Other Exchanges
Address
74, Noryangjin-ro, Dongjak-gu, Seoul, KOR
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplement, household and animal care, and contract manufacturing of active pharmaceutical ingredients. Yuhan offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.

Yuhan (XKRX:000100) Headlines

No Headlines